购物车
- 全部删除
- 您的购物车当前为空
PTC-209 hydrobromide (PTC-209 HBr) 是一种特定的BMI-1抑制剂,能不可逆转地损害结直肠癌起始细胞,也可损害肿瘤微环境,有抗骨髓瘤活性。它在 HEK293T 细胞系中的IC50为 0.5 μM。
PTC-209 hydrobromide (PTC-209 HBr) 是一种特定的BMI-1抑制剂,能不可逆转地损害结直肠癌起始细胞,也可损害肿瘤微环境,有抗骨髓瘤活性。它在 HEK293T 细胞系中的IC50为 0.5 μM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 517 | 5日内发货 | |
5 mg | ¥ 849 | 5日内发货 | |
100 mg | ¥ 6,960 | 1-2周 |
产品描述 | PTC-209 hydrobromide (PTC-209 HBr) is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs). |
靶点活性 | BMI1:0.5 μM |
体外活性 | PTC-209在人类结直肠癌细胞HCT116和人类纤维肉瘤细胞HT1080中同时抑制UTR介导的报告基因表达和内源性BMI-1表达。PTC-209通过BMI-1依赖的方式减缓结直肠肿瘤细胞生长。此外,PTC-209还通过不可逆的生长抑制作用损害结直肠癌起始细胞(CICs)。[1] |
体内活性 | PTC-209(60 mg/kg/天,皮下注射)有效抑制了肿瘤组织中BMI-1的产生,并在带有初级人类结肠癌异种移植物、人类结肠癌细胞系LIM1215或HCT116异种移植物的小鼠中停止了已建立肿瘤的生长。PTC-209还在体内减少了功能性结直肠CICs的频率。[1] |
激酶实验 | Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control. |
细胞实验 | To determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference) |
别名 | PTC-209 HBr |
分子量 | 576.1 |
分子式 | C17H13Br2N5OS·HBr |
CAS No. | 1217022-63-3 |
密度 | 1.31g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | Ethanol: <1 mg/mL H2O: <1 mg/mL DMSO: 93 mg/mL (161.4 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容